RxDoctor Payments Data

Elvis Cami, MD

Cardiovascular Disease · Royal Oak, MINPI 1194045047

Payments from drug & device makers

$45,358in general payments, 2019–2025

Across 152 payments — averaging $298.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$38K
  • Edwards Lifesciences$5K
  • Boston Scientific$771
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$479
  • Abbott$411
  • Medtronic$210
  • plus $622 from 11 others

What the payments were for

  • Consulting fees$17,13138%
  • Speaking & faculty fees$19,00842%
  • Travel & lodging$3,7278%
  • Food & beverage$5,49312%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,358 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$135,221
Medicare patients
1,090
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$152,320
Repatha SureclickEvolocumab94$63,510
EntrestoSacubitril/Valsartan40$50,949
FarxigaDapagliflozin Propanediol35$38,059
JardianceEmpagliflozin20$31,175
XareltoRivaroxaban21$23,578
Praluent PenAlirocumab13$6,321
Rosuvastatin Calcium178$3,470
Atorvastatin Calcium147$2,253
Ezetimibe73$1,386
Metoprolol Succinate94$1,281
ClopidogrelClopidogrel Bisulfate63$1,240
Losartan Potassium91$1,149
Carvedilol85$1,048
Valsartan19$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$152,320112 claims
NovartisEntresto$102$50,94940 claims
Johnson & JohnsonXarelto$40$23,57821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →